NASDAQ:SRNE - Sorrento Therapeutics Stock Price, News & Analysis

$2.10
-0.16 (-7.08 %)
(As of 08/23/2019 04:00 PM ET)
Today's Range
$2.09
Now: $2.10
$2.29
50-Day Range
$2.0650
MA: $2.40
$2.82
52-Week Range
$1.80
Now: $2.10
$6.50
Volume605,815 shs
Average Volume657,553 shs
Market Capitalization$275.06 million
P/E RatioN/A
Dividend YieldN/A
Beta2.34
Sorrento Therapeutics, Inc, a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide. It offers resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for the treatment of intractable pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. Read More…

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SRNE
CUSIPN/A
Phone858-203-4100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$21.19 million
Book Value$0.42 per share

Profitability

Net Income$-203,540,000.00
Net Margins-1,107.37%

Miscellaneous

Employees382
Market Cap$275.06 million
Next Earnings Date8/29/2019 (Estimated)
OptionableOptionable

Receive SRNE News and Ratings via Email

Sign-up to receive the latest news and ratings for SRNE and its competitors with MarketBeat's FREE daily newsletter.


Sorrento Therapeutics (NASDAQ:SRNE) Frequently Asked Questions

What is Sorrento Therapeutics' stock symbol?

Sorrento Therapeutics trades on the NASDAQ under the ticker symbol "SRNE."

When is Sorrento Therapeutics' next earnings date?

Sorrento Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, August 29th 2019. View Earnings Estimates for Sorrento Therapeutics.

What price target have analysts set for SRNE?

3 equities research analysts have issued twelve-month target prices for Sorrento Therapeutics' shares. Their predictions range from $10.00 to $30.00. On average, they anticipate Sorrento Therapeutics' stock price to reach $17.3333 in the next twelve months. This suggests a possible upside of 725.4% from the stock's current price. View Analyst Price Targets for Sorrento Therapeutics.

What is the consensus analysts' recommendation for Sorrento Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sorrento Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sorrento Therapeutics.

What are Wall Street analysts saying about Sorrento Therapeutics stock?

Here are some recent quotes from research analysts about Sorrento Therapeutics stock:
  • 1. According to Zacks Investment Research, "Sorrento Therapeutics, Inc. is a biopharmaceutical company. It is focused primarily on the acquisition, discovery, development and commercialization of proprietary oncology therapeutics. The Company researches human therapeutic antibodies for the treatment of cancer, inflammation, metabolic disease and infectious disease. Sorrento Therapeutics, Inc. is based in San Diego, California. " (8/22/2019)
  • 2. HC Wainwright analysts commented, "We ascribe a value of $5.5B based on a sum- of-the-parts approach, or a price per share of $30.00, assuming 183M projected fully-diluted shares outstanding as of mid-2020." (8/12/2019)

Has Sorrento Therapeutics been receiving favorable news coverage?

Media coverage about SRNE stock has trended positive this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Sorrento Therapeutics earned a daily sentiment score of 2.5 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the company's share price in the near term. View News Stories for Sorrento Therapeutics.

Who are some of Sorrento Therapeutics' key competitors?

What other stocks do shareholders of Sorrento Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sorrento Therapeutics investors own include Synergy Pharmaceuticals (SGYP), Cara Therapeutics (CARA), Novavax (NVAX), Micron Technology (MU), Viking Therapeutics (VKTX), Gilead Sciences (GILD), Alibaba Group (BABA), Canopy Growth (CGC), Eyepoint Pharmaceuticals (EYPT) and TG Therapeutics (TGTX).

Who are Sorrento Therapeutics' key executives?

Sorrento Therapeutics' management team includes the folowing people:
  • Dr. Henry H. Ji, Co-Founder, Chairman, CEO & Pres (Age 55)
  • Dr. Jerome Bernard Zeldis, Chief Medical Officer & Pres of Clinical Devel. (Age 69)
  • Mr. George K. Ng, Corp. Sec. (Age 45)
  • Mr. Jiong Shao M.B.A., CFA, Exec. VP & CFO (Age 51)
  • Ms. Deborah H. Telman, Sr. VP & Gen. Counsel

Who are Sorrento Therapeutics' major shareholders?

Sorrento Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.37%), Vanguard Group Inc. (3.92%), CVI Holdings LLC (1.07%), Northern Trust Corp (1.10%), Bank of New York Mellon Corp (0.37%) and Parametric Portfolio Associates LLC (0.25%). Company insiders that own Sorrento Therapeutics stock include Abg Management Ltd, George K Ng and Pacific Medtech (Bvi) Ltd Asia. View Institutional Ownership Trends for Sorrento Therapeutics.

Which major investors are selling Sorrento Therapeutics stock?

SRNE stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Morgan Stanley, AXA, Virtus ETF Advisers LLC and BNP Paribas Arbitrage SA. View Insider Buying and Selling for Sorrento Therapeutics.

Which major investors are buying Sorrento Therapeutics stock?

SRNE stock was acquired by a variety of institutional investors in the last quarter, including CVI Holdings LLC, Vanguard Group Inc., BlackRock Inc., Charles Schwab Investment Management Inc., Price T Rowe Associates Inc. MD, Bank of America Corp DE, Centaurus Financial Inc. and Northern Trust Corp. View Insider Buying and Selling for Sorrento Therapeutics.

How do I buy shares of Sorrento Therapeutics?

Shares of SRNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sorrento Therapeutics' stock price today?

One share of SRNE stock can currently be purchased for approximately $2.10.

How big of a company is Sorrento Therapeutics?

Sorrento Therapeutics has a market capitalization of $275.06 million and generates $21.19 million in revenue each year. The biopharmaceutical company earns $-203,540,000.00 in net income (profit) each year or ($1.92) on an earnings per share basis. Sorrento Therapeutics employs 382 workers across the globe.View Additional Information About Sorrento Therapeutics.

What is Sorrento Therapeutics' official website?

The official website for Sorrento Therapeutics is http://www.sorrentotherapeutics.com/.

How can I contact Sorrento Therapeutics?

Sorrento Therapeutics' mailing address is 4955 DIRECTORS PLACE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-203-4100 or via email at [email protected]


MarketBeat Community Rating for Sorrento Therapeutics (NASDAQ SRNE)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  459 (Vote Outperform)
Underperform Votes:  260 (Vote Underperform)
Total Votes:  719
MarketBeat's community ratings are surveys of what our community members think about Sorrento Therapeutics and other stocks. Vote "Outperform" if you believe SRNE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRNE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel